Locally Advanced Pancreatic Adenocarcinoma Pancreatic
Phase of Development |
Phase 2 |
Status |
Study Launch Expected in Q1 2023 |
Number of Subjects |
Up to 90 |
Study Drug |
Ampligen® Following FOLFIRINOX |
Primary Endpoint |
PFS |
Secondary Endpoint |
OS, ORR, DoR |
Clinical Trials NCT # |
NCT05494697 |
Late-Stage Pancreatic Cancer
Phase of Development |
Early Access Program |
Status |
Ongoing |
Number of Subjects |
40+ |
Study Drug |
Ampligen® Monotherapy |
Primary Endpoint |
Safety and Efficacy |
Study Partner |
Erasmus MC |
Data Publication |
Positive ResultsPublished March 2022 |
Advanced, Recurrent Ovarian Cancer
Phase of Development |
Phase 1/2 |
Status |
Interim Data Published April 2022 |
Number of Subjects |
45 |
Study Drug |
Ampligen®; Cisplatin; Pembrolizumab |
Primary Endpoint |
Objective Response Rate (ORR) |
Study Partner |
University of Pittsburgh |
Clinical Trials NCT # |
NCT03734692 |
Recurrent Ovarian Cancer
Phase of Development |
Phase 1/2 |
Status |
|
Number of Subjects |
25 |
Study Drug |
Ampligen®; Cisplatin; Celecoxib; DC vaccine |
Primary Endpoint |
Treatment |
Study Partner |
University of Pittsburgh |
Clinical Trials NCT # |
NCT02432378 |
Metastatic Triple Negative Breast Cancer
Phase of Development |
Phase 1 |
Status |
Data Published April 2022 |
Number of Subjects |
8 |
Study Drug |
Ampligen®; Celecoxib; Pembrolizumab; Recombinant Interferon Alfa-2b |
Primary Endpoint |
Overall response rate (ORR) |
Study Partner |
Roswell Park Cancer Institute |
Clinical Trials NCT # |
NCT03599453 |
Early-Stage Triple Negative Breast Cancer
Phase of Development |
Phase 1 |
Status |
Analyzing Data |
Number of Subjects |
24 |
Study Drug |
Ampligen®; Celecoxib; Cyclophosphamide; Doxorubicin Hydrochloride; Paclitaxel; Recombinant Interferon Alfa-2b |
Primary Endpoint |
Tumor-infiltrating CD8+ cytotoxic T lymphocyte (CTL)s |
Study Partner |
Roswell Park Cancer Institute |
Clinical Trials NCT # |
NCT04081389 |
Colorectal Cancer Metastatic to the Liver
Phase of Development |
Phase 2a |
Status |
Final Data Published April 2022 |
Number of Subjects |
19 |
Study Drug |
Ampligen®; Celecoxib; Recombinant Interferon Alfa-2b |
Primary Endpoint |
Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions |
Study Partner |
Roswell Park Cancer Institute |
Clinical Trials NCT # |
NCT03403634 |
COVID-19 in Cancer Patients
Phase of Development |
Phase 1/2 |
Status |
Recruiting |
Number of Subjects |
Up to 64 |
Study Drug |
Ampligen® and IFN alpha-2b |
Primary Endpoint |
Incidence of AEs, Kinetics of Viral Load |
Study Partner |
Roswell Park |
Clinical Trials NCT # |
NCT04379518 |
Refractory Melanoma
Phase of Development |
Phase 2 |
Status |
Enrollment Ongoing |
Number of Subjects |
24 |
Study Drug |
Ampligen®; Celecoxib; PD-1 Ligand Inhibitor; PD1 Inhibitor; Recombinant Interferon Alfa-2b |
Primary Endpoint |
Objective response rate (ORR) |
Study Partner |
Roswell Park Cancer Institute |
Clinical Trials NCT # |
NCT04093323 |